Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation
Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).